Amphastar Pharmaceuticals, Inc. cotiza a 26.05 USD y tiene una capitalización bursátil de $1.1B. En los últimos 12 meses ha facturado $730M con un margen de flujo de caja libre del 16.8%. Cotiza a 7.3 veces su flujo de caja libre (P/FCF) y a un PER de 14.1. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; P…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $0.91 | $0.42 | $0.73 |
| Estimado | $0.73 | $0.61 | $0.71 | $0.92 |
| Sorpresa | — | +49.2% | -40.8% | -20.7% |
| Métrica | AMPH | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 49.5% | 57.0% | -7.6% |
| Operating Margin | 19.5% | -38.6% | +58.1% |
| Net Margin | 13.6% | -33.6% | +47.2% |
| FCF Margin | 16.8% | -13.9% | +30.7% |
| ROE | 12.4% | -40.4% | +52.8% |
| ROA | 6.0% | -32.0% | +38.0% |
| Current Ratio | 4.02 | 2.84 | +1.18 |
| Debt / Equity | 0.79 | 0.28 | +0.51 |